Probio Cayman, a subsidiary of Hong Kong-listed Genscript Biotech, has entered into an agreement to raise about $150 million from private equity firm Hillhouse Capital Group, the parent firm disclosed in a filing with the Hong Kong stock exchange on Thursday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
